the pharmaceutical industry devoting huge resources cancer research development relation sales existing drugs although reliable figures available industry sources estimate companies worldwide spend dollars 3bn pounds 2bn year cancer rd us companies responsible half total the cancer therapeutics market worth dollars 65bn year according frost sullivan international market research company 38 per cent us 26 per cent europe 36 per cent rest world the leading suppliers zeneca uk whose tamoxifen best sellingcancer drug dollars 550m sales 1993 bristolmyers squibb us devoting almost 50 per cent sales revenues rd high figure indeed says david barrett bristolmyers squibbs strategic projects director the industrys overall rd expenditure 15 per cent drug sales the main reason cancer spending high disease top industrys priority list unmet needs although deaths heart disease twice cancer falling cardiologists already much wider range effective treatments oncologists at time scientific advances giving many new leads traditional drug companies emerging biotechnology sector the world 1000 experimental cancer drugs rd pipeline analysts decision resources frost sullivan predict continued growth 10 per cent year cancer market next century it expected exceed dollars 10bn 1998 the industrys cancer rd spending matched dollars 3bn year worlds governments charities by far largest contributor us national cancer institute receives dollars 2bn year federal funding the charitable sector particularly important uk imperial cancer research fund cancer research campaign spend pounds 100m year 10 times much statefunded medical research council